BiolineRX Raises $24M On Secondary Nasdaq Offering

March 9, 2014 | Israeli biomed company BiolineRX held a secondary public offering on Nasdaq. The offering is considered a success, as the company surpassed its goal of $21 million, raising $24 million. The company said that it will use the proceeds for clinical trials of its leukemia and celiac disease treatments.